Select campus:UKDubai
University of Birmingham
Menu

Endovascular treatment more likely to avoid amputation or death for limb-threatening artery disease

In the only randomised controlled trial of its kind, BASIL-2 enrolled 345 patients in 41 vascular surgery centres in UK, Sweden and Denmark

2 May 2023
Two surgeons wearing blue gowns, one reaching for a surgical tool in an operating theatre

In patients with chronic limb threatening ischaemia (CLTI) due to atherosclerosis affecting the arteries below the knee, data from the first clinical trial of its kind shows that a best endovascular treatment first revascularisation strategy was more likely to prevent major amputation and death than a vein bypass first strategy.

Published in the Lancet, the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL-2) randomised controlled trial (RCT), which was run through the University of Birmingham Clinical Trials Unit (BCTU), and which was funded by the National Institute for Health and Care Research (NIHR), compared two revascularisation strategies for restoring limb perfusion in patients with chronic limb-threatening ischaemia (CLTI) due to atherosclerosis affecting the arteries below the knee.

Patients from the UK, Sweden and Denmark were randomly assigned to either a vein bypass (VB) first or a best endovascular treatment (BET) first revascularisation strategy.

Patients who were randomised to VB first were one third more likely to require a major amputation or die during follow-up than patients who were randomised to BET, which in most cases comprised plain balloon angioplasty with selective use of stents.

Professor Andrew Bradbury, Sampson Gamgee Professor of Vascular Surgery at the University of Birmingham and Chief Investigator of the BASIL-2 trial said:

“Patients with chronic limb-threatening ischaemia generally have very poor prognosis and optimal strategies for restoring limb perfusion remain incompletely defined. BASIL-2 is only the third published RCT in patients with CLTI, and the only one to have specifically recruited patients who required intervention to arteries below the knee to restore blood flow to the lower leg and foot.

“There were many challenges to recruitment and follow-up, most recently due to the COVID-19 pandemic. However, BASIL-2 has now produced a statistically robust and clinically meaningful result that is likely to have an influence on the management of CLTI worldwide”

Professor Andrew Farmer, Director of NIHR’s Health Technology Assessment (HTA) Programme, which funded the trial, said:

“The findings of this important study are likely to greatly improve treatments for patients with this life-threatening and debilitating condition. Once again NIHR-funded research is providing vital evidence to drive forward outcomes for patients and better ways of delivering care for the NHS for those who plan and deliver services."

Notes for editors

  • Full citation: Bradbury, A.W., et al, 2023, A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. The Lancet, DOI: 10.1016/S0140-6736(23)00462-2
  • For media enquiries please contact Tim Mayo, Press Office, University of Birmingham, tel: +44 (0)7920 405040
  • The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 6,500 international students from over 150 countries.
  • The University of Birmingham is a founding member of Birmingham Health Partners (BHP), a strategic alliance which transcends organisational boundaries to rapidly translate healthcare research findings into new diagnostics, drugs and devices for patients. Birmingham Health Partners is a strategic alliance between seven organisations who collaborate to bring healthcare innovations through to clinical application:
    • University of Birmingham
    • University Hospitals Birmingham NHS Foundation Trust
    • Birmingham Women's and Children's Hospitals NHS Foundation Trust
    • Aston University
    • The Royal Orthopaedic Hospital NHS Foundation Trust
    • Sandwell and West Birmingham Hospitals NHS Trust
    • West Midlands Academic Health Science Network

  • The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:
    • Funding high quality, timely research that benefits the NHS, public health and social care;
    • Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
    • Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
    • Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
    • Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
    • Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.
  • NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.

 

Featured staff

  • Professor Andrew Bradbury

    Sampson Gamgee Professor of Vascular Surgery and Director of Quality Assurance and Enhancement

    Staff profile for Professor Andrew Bradbury, Professor of Vascular Surgery, Department of Cardiovascular Sciences at the University of Birmingham

    Phone: +44 (0)121 424 5086 (PA)
    Email: a.w.bradbury@bham.ac.uk

More in Health & medicine